Michelle C. Boyer

Welwyn Garden City, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up.

Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up.

Journal: American journal of hematology
Published: July 29, 2025

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Journal: Blood
Published: July 25, 2025

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Journal: Blood
Published: July 25, 2025

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.

Journal: HemaSphere
Published: June 06, 2025

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

Journal: Blood
Published: May 28, 2024

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Journal: Blood
Published: April 08, 2024

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.

Journal: HemaSphere
Published: October 20, 2023

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Journal: Blood advances
Published: September 20, 2023

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

Journal: Blood advances
Published: April 08, 2022

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.

Journal: EJHaem
Published: December 10, 2021

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

Journal: Blood
Published: December 01, 2021

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Journal: The Lancet. Haematology
Published: November 12, 2021
Showing 1-12 of 23

Last Updated: 09/26/2026